RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Viva Biotech, a Shanghai CRO, raised $194 million in its Hong Kong IPO, and then traded higher in public trading, ending the week with a 14% gain. Viva is a structure-based, integrated drug discovery CRO that offers an Equity for Service model to selected clients. The IPO attracted the heaviest investor interest of any of the first eight Hong Kong pre-revenue biotech IPOs, which caused the underwriters to send more shares to local investors and fewer to international buyers. The IPO priced at the top of the expected range.
Source: China Biotoday
